Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA lifts Cloretazine hold

Vion (NASDQ:VION) said FDA lifted a clinical hold on a Phase III trial (Study CLI-037) of Cloretazine ( VNP40101M) plus cytarabine to treat

Read the full 237 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE